Search

Efficient magnetic solid phase extraction using crystalline porous polymers can find important applications in food safety. Herein, the core-shell Fe

BACKGROUND Intensity-modulated radiotherapy (IMRT) is the standard treatment for patients with nasopharyngeal cancer (NPC). However, the dose-volume criteria for adjacent anatomically normal organs at risk (OARs) remain controversial. The aim of this study was to evaluate the effects of higher than conventional doses of static and dynamic IMRT on the locoregional control of NPC, patient survival, and brainstem radiation toxicity. MATERIAL AND METHODS Patients (n=186) with stage III and stage IVa NPC underwent high-dose static and dynamic IMRT treatment (68-76.96 Gy) with or without chemotherapy for 34-57 days. Overall survival (OS), the presence of distant metastases, and brainstem toxicity were assessed. One-year, three-year, and five-year follow-up was performed. RESULTS High-dose IMRT alone or in combination with chemotherapy resulted in a 100% objective response rate and significantly improved OS rates, with one-year, three-year, and five-year OS rates of 94.1%, 89.8%, and 88.2%, respectively. The local recurrence rate (17.6%), and distant metastasis to the lung, liver, and bone (17.2%), and mortality (n=22) were reduced. Chemotherapy was the only factor that was significantly correlated with patient survival. Brainstem toxicity was reduced in patients treated with static IMRT (0.07%) and dynamic IMRT (0.08%). There were 26 additional factors that were not found to significantly affect brainstem toxicity. CONCLUSIONS High-dose static or dynamic IMRT combined with chemotherapy improved survival and reduces distal metastasis with a very low occurrence of brainstem toxicity in patients with locally advanced NPC. These findings might provide therapeutic guidance for clinicians when planning optimal dose-volume IMRT parameters.

Temperature is one of the most important parameters to evaluate the status of electric equipments. In this paper, a temperature monitor and query system based on virtual instruments and infrared temperature monitoring technical is introduced, including the hardware build-up and software realization. The system a multiple function system, including measurement and control parameter setting; data acquisition and processing; data, chart and graph displaying; signal processing and analyzing; data saving and so on. It can meet the need of the precision request in the temperature measurement of electrical equipment. Also it can be applied in other related experiments and developed further.

The aim of this study was to investigate the expression of ubiquitin-specific peptidase 9, X-linked (USP9X) in non-small cell lung cancer (NSCLC) patients and to evaluate the relevance of USP9X expression to tumor prognosis.Ninety-five patients who underwent surgical resection for clinical stage I-IIIA NSCLC between July 2008 and July 2011 were included in this study. Immunohistochemical analysis of USP9X expression was performed on 95 NSCLC tissues and 32 adjacent normal lung parenchymal tissues from these patients. The Chi-squared test was used to compare the clinicopathological characteristics between different groups. Kaplan-Meier analysis and a Cox regression model were used to determine the independent prognostic factors. A P value0.05 was considered to be significant.The expression of USP9X was found to be significantly higher in NSCLC tissue (44.2%) than in adjacent normal lung parenchymal tissue (6.3%) (P0.001). High USP9X expression was significantly associated with positive lymph node metastasis (P0.001), clinical stage (P0.001) and a reduced overall survival rate (P=0.001) in patients with NSCLC. Based on the multivariate analysis, the elevated expression of the USP9X protein was a significant predictor of poor prognosis for NSCLC patients (HR =2.244, P=0.028).The current study demonstrated that the expression of USP9X in NSCLC tissue was significantly higher than that in normal lung tissue and that this elevated expression level of USP9X was associated with poor prognosis among NSCLC patients, suggesting that USP9X might serve as a prognostic biomarker for NSCLC.

Internal and external physiological research showed oxaliplatin could obviously suppress several kinds of tumors in combination with most anti-cancer drugs and help these drugs to kill the tumor cells. This study was designed to investigate the initial curative effects and tolerance of patients with advanced gastric cancer of treatment with combination of oxaliplatin (L-OHP) and hydroxycamptothecine (HCPT). We compared this treatment with traditional chemotherapy.In a non-randomized manner, 43 patients with advanced gastric cancer were divided into treatment group (L-OHP plus HCPT) and control group (VP-16 + CF + 5-FU) (ELF). Among these patients, 28 were male and 15 were female. The median age was 59. Karnofsky performance status(KPS) scale was more than 60. We compared the initial curative effects and tolerance between these two groups.The beneficial effects for the treatment group (24 cases) and control group (19 cases) were 58.3% (14/24) and 42.1% (8/19), respectively. Obviously, the beneficial effects to the treatment group were higher than that of the control group (P0.05). The side effects of both groups included bone marrow suppression, nausea, vomiting, stomatitis, neuritis, phlebitis, hair loss, and so on. But they were slight (within I and II degree).The use of L-OHP plus HCPT appears to be a very good treatment for patients with advanced gastric cancer. The patients can tolerate the side effects.